Towards Laser Driven Hadron Cancer Radiotherapy: A Review of Progress by Ledingham, K. W. D. et al.
 1 
Towards Laser Driven Hadron Cancer Radiotherapy:  
A Review of Progress 
 
K.W.D. Ledingham, 
SUPA, Department of Physics, University of Strathclyde, Glasgow G40NG, Scotland 
 and Universıty of Selcuk, Faculty of Science, Department of Physics, 
Konya, 42031,Turkey 
 
P.R. Bolton, N. Shikazono, 
Kansai Photon Science Institute, Japan Atomic Energy Agency, 
8-1-7 Umemidai, Kizugawa, Kyoto 619-0215,  
 
C-M. Ma  
Radiation Oncology Department, Fox Chase Cancer Center,  
7701 Borehole Ave., Philadelphia 19111, USA 
 
 
Abstract 
 
It has been known for about sixty years that proton and heavy ion therapy is a very 
powerful radiation procedure for treating tumours.  It has an innate ability to irradiate 
tumours with greater doses and spatial selectivity compared with electron and photon 
therapy and hence is a tissue sparing procedure.  For more than twenty years powerful 
lasers have generated high energy beams of protons and heavy ions and hence it has 
been frequently speculated that lasers could be used as an alternative to RF accelerators 
to produce the particle beams necessary for cancer therapy. The present paper reviews 
the progress made towards laser driven hadron cancer therapy and what has still to be 
accomplished to realise its inherent enormous potential.  
 
Contents 
 
Preamble            2 
Introduction                                                                                                           3                                                                                                              
1.Laser Driven Pulsed Ion Beams                    4 
     1.1 Typical Ion Energy Spectra       5 
     1.2 Spectral Control [with lasers and targets]     7 
     1.3 Angular Divergence Control [target as an ion optic]               12 
2. Beam Transport and Delivery Considerations      13 
3. Laser Driven Electron Beams for Radiotherapy      16 
4. Cellular basis of laser driven radiation therapy      17 
       4.1 Important factors for determining cellular radiation effect   18 
       4.2 DNA Damage Sequence and Biological Effects    19 
       4.3 Dose Rate Picture        20 
       4.4 Oxygen Effect and Dose Rate      22 
       4.5 Laser Driven radiation in radiobiological studies    22 
5. Real Time identification of healthy and cancerous tissue using laser                     23 
    desorption ionization mass spectrometry                  
6. Some notable sites [current and planned] exploring laser driven particle               25 
    acceleration and potential medical applications 
 2 
      a) Queens University Belfast Consortium      25 
      b)   Laboratoire d’Optique Appliquee- LOA, Palaiseau, France    26 
      c)   Ion Acceleration Program at BNL ATF and UCLA     26 
d) OncoRay-National Center for Radiation Research in Oncology, Dresden    27 
      e)   Laser Acceleration Studies at JAEA in Japan                                       28 
      f)   The Munich Centre for Advanced Photonics [MAP]     29 
      g)   ELIMED Prague                                                                           29                                                              
      h)   Selcuk/Strathclyde Consortium Konya, Turkey                                               30 
 7. Comparative radiotherapy costs        30 
8. Discussion and conclusions       32 
References          34 
 
Preamble  
 
About 4% of people in developed countries are diagnosed with cancer each year and 
more than 50% of these patients receive radiation treatment, making radiotherapy along 
with surgery the most common as well as the most successful form of cancer therapy. 
Although radiotherapy is predominantly performed using photons, proton therapy is 
quickly gaining popularity due to its ability to irradiate tumours with higher doses and 
greater spatial selectivity (localization). This means that with protons (and other ions) 
healthy tissue can be more readily spared during irradiation than using electron or 
photon therapy. However, patient access to proton and heavy ion (C+6) treatment is 
highly restricted due to high cost and consequent limited availability.  
 
The use of charged hadrons in cancer therapy is almost as old as the discovery and 
development of the cyclotron in 1932.  The first suggestion that fast protons could be 
used in radiology was made by “Bob” Wilson in 1946 (1) although it was not until 1954 
that the first patients were treated. According to Wikipedia (2) 
(http://en.wikipedia.org/wiki/Proton_therapy), as of 2012 there were 39 particle 
therapy facilities in the world located in Canada, China, Czech Republic, France, 
Germany, Italy, Japan South Korea, Poland, Russia, South Africa, Sweden, 
Switzerland, the UK and the USA. More than 50% of the centres however are in the 
USA and Japan.  Almost 100,000 patients have been treated with hadrons (protons and 
carbon ions).  To treat tumours that are deeply seated within the body, proton energies 
above 250 MeV are needed while for carbon ions 400 MeV/amu is required.  
 
Nonetheless, radiotherapy using accelerator based hadron beams is well-established. A 
selection of the many excellent publications on this subject is given in references (3-
11). The authors of reference (3) claimed that “if 200 MeV proton accelerators would 
be as cheap and small as the 10 MeV electron linacs used in conventional radiotherapy, 
at least 90% of the patients would be treated with proton beams”.  This indicates how 
effective hadron therapy is in cancer treatment.  However caution must be exercised 
with this statement because there are very few randomized controlled trials comparing 
treatment with protons and photons (we further address this issue later in this work).  
 
As stated earlier, what is hampering the wider application (and access) of this therapy 
mode around the world is the high cost of these centres.  The authors of (3) estimate 
that the cost of establishing a conventional accelerator-based hadron therapy centre is 
in the range, 130-150M€ which is prohibitive for many developing countries (relevant 
cost comparisons will be subsequently addressed in this work). 
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Regarding future perspectives, the authors of (3) have stated that “further in the future, 
the first proton single room facility based on the illumination of a thin target with 
powerful (1018 - 1020 W/cm2) and short (30-50fs) laser pulse is expected”. The basis of 
their statement is a shared optimism that the cost and size of laser-based proton therapy 
centres might be greatly reduced in the future (5). Reduced cost and size will be critical 
for facilitating general access to hadron radiotherapy. In fact, a reasonable design 
constraint for the future is that full systems (novel sources, laser-based or otherwise, 
and other associated treatment components) should be accommodated within the 
infrastructure of existing hospitals (a consistent prediction has been made by Malka et 
al (see section 1.3 )) 
 
The overall challenge for laser-driven ion beam radiotherapy is to develop well-
controlled, reliable energetic ion beams of very high quality that can meet stringent 
medical requirements with respect to physical parameters and performance and 
therefore represent a viable alternative in an advancing state-of-the-art for radiotherapy.  
 
Introduction 
 
The history of innovative laser applications demonstrates its ubiquitous character. The 
feasibility of using lasers for hadron radiotherapy has been considered for more than a 
decade based on energetic ion yields from intense laser-plasma experiments. It has been 
one of the main applications considered in laser-driven ion acceleration studies (17-22). 
We also include in this work laser driven electron beams for radiation therapy and 
radiobiology (23,24) as well as laser driven proton beams for radiobiological studies 
(25-27).  Moreover for completeness we have included finally a section dealing with 
laser driven fragmentation studies as a very recent cancerous tissue diagnostic which 
has received much attention in the last year (120-124) 
 
Laser technology and relevant laser-plasma physics as drivers are advancing rapidly. 
Outstanding progress has been made in high-power laser technology in the last decade 
with laser powers reaching the petawatt (PW) level. At present, there are fifteen PW 
lasers built or being built around the world while even higher power lasers (exawatt and 
beyond) are being considered by some. With adequate focusing petawatt lasers can 
generate peak electric fields of order 1012 V/cm with relatively efficient conversion to 
relativistic electrons with energies in excess of 1 GeV. In turn these electrons can 
generate beams of protons, heavy ions, neutrons and high-energy photons. Given the 
potential for energetic laser-driven particles we can now consider experiments in laser 
laboratories that are normally associated with conventional nuclear accelerators and 
reactors. A number of reviews describing the production of ion and electron beams by 
intense laser irradiation have been published during the last few years e.g. (13-16).  
 
In 2007 (28) Linz and Alonso published a seminal paper entitled “What will it take for 
laser driven proton accelerators to be applied to tumour therapy” which acknowledged 
the potential of a compact laser based system but warned that the optimism of laser 
physicists should not raise undue expectations in the medical community.  Reduced 
cost and size are shared general aims in laser-driven particle beam development for 
radiotherapy. However, many scientific and technical challenges must first be met to 
achieve this and to confirm unique laser-driver capabilities. Reaching medically 
relevant particle kinetic energies is obviously essential, yet equally important is the 
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demonstration of repetition-rated, well-controlled beamlines at these energies with 
suitable bunch parameters that are highly reproducible. A systems mindset is necessary 
to incorporate, optimize and even exploit the multiple technologies that must be 
combined. We can refer to the full system as the integrated laser-driven ion accelerator 
system or ILDIAS (ILDEAS for electrons). ILDIAS components therefore include the 
laser driver, the laser target, instrumentation for diagnostics and control and beam line 
(ion) optics. In this novel accelerator we can regard the laser plus target (which includes 
the induced laser-plasma at the target) as the accelerator source.   
 
The limited scope of this work is to review global progress toward laser-driven hadron 
therapy specifically in terms of particle kinetic energy and other intrinsic source 
features (such as angular divergence and duration of the emitted particle bunch) of the 
laser-driven acceleration in a plasma environment.  
 
1. Pulsed Ion Beams (protons and carbon ions): Laser-driven Source 
Features 
 
Proton and heavy ion therapy are important and efficient sources of therapeutic 
irradiation on account of the capability for dose localization.  Fig. 1 illustrates the well- 
known relative dose of therapeutic irradiation beams as a function of depth in tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 The relative radiation dose deposited as a function of tissue depth for various particle and photon 
beams 
 
It can be seen that commonly used X-ray beams feature a maximum dose at a shallow 
tissue depth but continue to deposit energy throughout the x-ray range.  On the other 
hand the maximum deposition of proton energy is near the end of its range (resulting in 
the well-known Bragg Peak phenomenon) which can coincide with tumour depth with 
an appropriate energy choice. Healthy tissue located upstream and downstream of the 
tumour is less affected by the irradiation. This localization defines the strength and 
effectiveness of the applied irradiation procedure.  Furthermore carbon ions are 
biologically more effective and feature improved dose localization over protons such 
that healthy tissue is better spared.  For example Fig. 1 shows that, for a tumour located 
about 32 cm into the body, the dosage would be maximised using 200 MeV protons 
while the dosage to healthy tissue would be significantly reduced compared to that from 
an x-ray beam. 
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1.1 Typical Ion Energy Spectra  
 
We do not discuss the laser acceleration processes in detail but refer readers to the many 
papers written on this subject; in particular, two new reviews (16 and 17 Macchi, 
Daido). The laser and target parameter regime relevant to the Target Normal Sheath 
Acceleration (TNSA) scheme (29-31) (or a variant of it) is the most studied. A 
conceptual description of this process is now given.  A short, high-intensity laser pulse 
is incident on a thin target of any number of different materials, which invariably has 
hydrogen-bearing contaminant layers on its surfaces. These targets are 
characteristically a few microns thick and because of this, the laser pulse is mostly 
reflected. The laser prepulse ionizes the front surface to form a preplasma of electrons 
and ions. The subsequent main laser pulse is partially absorbed in this preplasma and 
accelerates the electrons in the forward direction to relativistic velocities (i.e. high 
temperatures) from the front surface to the back surface. The hot electrons and cool 
ions at the target back surface generate a charge separation and therefore an electrostatic 
extraction field over a few microns which accelerates back-surface protons and other 
ions in this field region. The whole process occurs within a vacuum environment. A 
sketch of the TNSA process is given in Fig. 2.  Extracting energetic particles from the 
vacuum then requires transmission through a thin vacuum window.  
 
 
Fig. 2 A simple sketch of ion beam generation and acceleration  by the TNSA mechanism showing the 
extreme laminarity of the beams. At this stage the beams are not neutral although quasi-neutrality 
becomes evident further from the target. 
 
Laser-accelerated ion spectra from thick targets feature a broad energy spread which is 
much greater than the monochromatic case typical of proton and heavy ion beams 
produced by conventional accelerators (in this work conventional means not laser-
driven). In fact, the energy spread in the TNSA regime can exceed 100% with relatively 
few ions at the higher energies needed for proton irradiation of deep seated tumours. 
Moreover laser driven ion beams at the source (laser target) have a characteristically 
wide angular divergence (half angle near 10-20o) as well as a short bunch duration (ps) 
which are very different from conventional accelerator produced beams. 
 
Fig.3 shows data taken using picosecond laser pulses provided by the Vulcan laser at 
the Rutherford Appleton Laboratory (STFC-RAL). The displayed spectral profile is 
quasi-exponential with a high energy cutoff or maximum value. Laser and target (i.e. 
combined source) parameters can determine the maximum proton energy. We note that 
there are fundamentally very few particles at the cutoff energy and that the cutoff value 
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is likely to be a demonstrably unstable (shot-to-shot) feature of the spectrum. It is not 
assumed to be an operation energy for a laser-driven accelerator. Instead, its value is in 
spectral characterization and comparison with simulated prediction. The scaling of the 
maximum proton energy using long pulse glass lasers (~ picosecond pulse duration) is 
shown in Fig 4. Fig. 5 shows its variation with pulse duration and laser power where it 
is clearly steeper for shorter pulse durations. The angular divergence of the emitted ion 
beam behind the target is much smaller than that in front of the target. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Proton energy spectrum from copper activation stacks in front of and behind the target.  Inserts 
show the first copper piece in each stack containing proton spatial information (32).  It should be pointed 
out that if radioactivity in activation stacks is used as a proton diagnostic then to be an unambiguous 
diagnostic for protons the nuclear reaction must be identified e.g using Cu activation stacks the 63Cu 
(p,n)62Cu with a 10 minute half-life was measured.  A number of authors have used just a general 
radioactive measurement as a diagnostic which unfortunately also includes neutron and photon activated 
sources of radioactivity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Maximum proton energy detected as a function of laser intensity obtained by variation of the laser 
pulse energy with a constant pulse duration of 1 ps for Al targets with thicknesses of 10 μm (red circles) 
and 25 μm (blue triangles). The open triangles correspond to laser shots on 25 μm targets for which the 
energy and pulse duration are both varied. The model data green curves is described in (33). 
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Fig. 5   Energy scaling of the accelerated protons as a function of the laser power on target as well as 
pulse width.  The many different contributions from various authors are given in  (34).  Reproduced by 
kind permission of the authors and the publishers. 
 
For a given laser power on target the maximum proton energy increases markedly with 
pulse duration as revealed in Fig. 5. At the time of writing the maximum reported proton 
energy was about 70 MeV in the TNSA acceleration regime. This is well below the 
energy necessary for ion beam treatment of deep seated tumours. However, ocular 
tumours could be treated at this energy. 
 
1.2 Spectral Control (with lasers and targets) 
 
Most of the early work on laser acceleration of ions was conducted with thick 
aluminium targets (micron). Using ultrashort laser pulses (33 fsec duration) with a high 
contrast ratio (1010) at the Lund Laser Centre, Neely and his team (35) showed that as 
the target thickness decreased from 30um to 100 nm the maximum proton energy and 
energy conversion efficiency (on target laser pulse energy to full spectrum proton 
kinetic energy) increased.  This is shown in Fig. 6.  
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Fig. 6 The proton spectra at 00 (target normal) and 140 (35) as a function of aluminium target thickness.  
The contrast ratio is ~1010 and laser intensity is ~1019 W/cm2. The maximum energy increases as the 
thickness decreases with a maximum near 100nm.  Reproduced by kind permission  of the authors and 
publishers. 
 
       However recent developments both theoretical and experimental in laser driven ion 
acceleration have shown considerable promise for increasing the maximum energy 
efficiency of the acceleration process taking advantage of the so-called transparent 
overdense regime (36-41). The transition to this regime occurs when the target is thin 
enough, typically tens to hundreds of nanometers, and the laser intensity and contrast 
are high enough, for all of the target electrons to be removed from the material during 
the laser-target interaction. Relativistic transparency enables the laser field to interact 
with the entire target while it is still overdense. As a result the entire ion population can 
be accelerated in unison. This induced dynamic transparency is a feature of both 
“Break-Out Afterburner” (BOA) Acceleration and Radiation Pressure Acceleration 
(RPA). BOA has been explored extensively over the last three years at the Los Alamos 
National Laboratory both experimentally and in simulations where it has been shown 
that ions (protons and carbon ions) of significantly increased energy can be produced. 
Close to 160 MeV protons and 700 MeV for fully ionised carbon ions are recorded (41-
43).  A proton spectrum obtained in the BOA regime is shown in Fig. 7. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 Proton spectra from the LANL Trident laser with 80J, 600fs pulses, r < 2μ spot size, target 
thickness 300,400nm with CH2 targets.  Reproduced by kind permission of the authors and publishers. 
 
Ion acceleration by laser light pressure (Radiation Pressure Acceleration –RPA) has 
also received a lot of attention recently because this mechanism can potentially 
accelerate ions to even higher energies (than TNSA or BOA) with significantly reduced 
energy spread and  much higher efficiency. We do not address the RPA regime in any 
detail and readers can consult the listed references (44-47).  Most of this work is 
theoretical and although a few experiments have been attempted significantly greater 
carbon ion energies must be reached in order to be clinically relevant (in this regime 
proton energies are reaching useful energies).  
 
Almost all of the laser-driven proton ion beam studies have used 0.8μ wavelength 
photons and laser pulse durations of either 1ps or 50-100 fs.  However recently very 
different laser parameters with another new mechanism have been applied to proton 
acceleration. Two groups, Haberberger et al (48) and Palmer et al (49) used an infrared 
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CO2 with a 10μ wavelength to investigate the collisionless shock-wave acceleration 
mechanism in a hydrogen plasma. A 60 J macropulse (which included a number of 3 
ps micropulses) produced almost monoenergetic 20 MeV proton bunches (~ 1 % energy 
spread) with very low emittance. Simulations indicate that ~200 MeV protons could be 
produced with the current CO2 laser technology. Moreover as laser technology 
improves and high power high repetition rate lasers are developed the use of a gaseous 
hydrogen beam target for proton acceleration can become more practical than solid 
targets which must be physically advanced between shots. This is shown in Fig. 8. In 
general however, to realize the clear rep-rate benefit typically afforded by gas sources 
the acceleration efficiency will need to be improved by orders of magnitude.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8  A linear polarised train of multiterawatt CO2 laser pulses interacting with a gas jet.  The laser 
with an intensity of 6.5x1016Wcm-2 produces a monoenergetic peak at about 20 MeV.  With an intensity 
of 7x1019Wcm-2 computer simulations showed the peak energy increased to ~170 MeV closer to the 
energy needed for proton therapy. Reproduced by kind permission of the authors and publishers (48). 
 
In 2008 Keitel (50) and his team studied theoretically the direct high power laser 
acceleration of ions specifically for medical applications and found that ions accelerated 
by radially polarised laser have generally a smaller energy spread than those accelerated 
by linearly polarised lasers of the same intensity. A radially polarised beam can be 
focused to smaller dimensions than a linearly or circularly polarised beam but 
unfortunately such lasers at the required power are not yet available. 
 
As described earlier laser-accelerated proton and heavy ion spectral profiles from thin 
foil targets are normally quasi-exponential. Quasi-monoenergetic spectra are desirable 
for ion beam radiotherapy.  
 
Schwoerer and his team produced quasi-monoenergetic protons by irradiating 
microstructured targets, an idea that had been suggested by Esirkepov et al in 2002, 
(51). The authors pointed out that the resulting proton spectrum has a strong correlation 
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to the spatial distribution of the protons on the target surface as shown in Fig. 9(a). A 
terawatt (TW) laser beam is focused on the front side of a metal target generating 
electrons, which establish a Debye sheath on the back surface as described earlier. 
Applying a small hydrogen-rich dot (a PMMA dot was used) on the back surface 
enhances the proton yield in the central part of the accelerating field, which is more 
homogeneous. This produces a noticeable peak in the proton spectrum as shown in Fig. 
9(b). The figure also includes PIC simulation results for the laser and target conditions 
used in the experiment. An inset in the figure estimates the anticipated proton spectrum 
at a laser intensity of 1021 Wcm-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 a) A laser incident on a proton dot deposited on a titanium substrate.  b) Experimental peaked 
proton spectrum (black dots) and PIC simulation (red curve). Reproduced by kind permission of the 
authors and publishers (52).  For other examples see (53) 
 
A number of authors however (e.g. Brantov et al 2006 (54), Robinson and Gibbon 2007 
(55)) pointed out this was not sufficient to explain quasi-monoenergetic features. They 
emphasized that a pure proton microdot target does not by itself result in a quasi-
monoenergetic proton beam. Such a beam can only be produced with a very lightly 
doped proton target in the presence of more abundant inert and heavier ions, which 
generate an electrostatic shock accelerating the protons away from the surface. Their 
simulations suggest that beam quality in current experiments could be considerably 
improved by choosing microdot compositions with a 5-10 times lower proton fraction. 
 
A laser-induced plasma optics (microlens) approach was adopted by Toncian et al 2006 
(56). As shown in Fig. 10, two CPA laser pulses were used (CPA means chirped pulse 
amplification). The CPA1 pulse produced a broad spectrum of protons from the foil 
target. Protons were directed downstream through a hollow metal cylinder irradiated by 
a second CPA2 laser pulse. The second laser beam induces a transient focusing (radial) 
electric field in the hollow cylinder. For a given target-cylinder spacing the relative 
timing between the two laser pulses can be varied (tuned) to select a range of proton 
energies for focusing and transmitted energy selection. 
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Fig. 10. An ultrafast laser-driven microlens to focus and energy select MeV protons. This technique is 
in principal scalable to high-energy protons. Reproduced by kind permission of the authors and the 
publishers (56). 
 
This technique addresses two of the current drawbacks of laser accelerated proton 
bunches namely their large energy spread and the angular divergence at the source. A 
similar outcome could be more easily achieved using small quadrupole or pulsed 
solenoid magnets, an approach that is being developed by several groups including the 
authors of this paper (57-59) also showing how the proton beam can be captured and 
transported.  More about transport of laser produced proton beams will be discussed in 
section 2. 
 
A number of other approaches to produce quasi-monoenergetic heavy ions have been 
reviewed previously e.g. monoenergetic deuterons from heavy water droplets (15). 
 
We now discuss very different target types that can be considered for achieving higher 
proton energies and proton focusing.   
 
Zigler, Botton and co-workers have recently shown (60) that enhanced proton 
acceleration can be produced with structured dynamic plasma targets.  These targets 
were engineered by depositing snow on sapphire substrates which mimicked the bristles 
on a brush. In this case the acceleration regime was not typically TNSA (Fig. 11) The 
laser interacted with one or more bristles to provide proton energies greater than that 
anticipated based on normal TNSA with thin film targets.  This behaviour is shown in 
Fig. 12. At laser powers greater than 1 PW the extrapolated simulation predicts proton 
energies near 200 MeV. 
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Fig. 11 Cartoon indicating how a laser beam interacts with snow pillars about 100μ in size.  The laser 
may interact with one or more pillars (purple arrows) and the protons come off (green arrows) from the 
target on the same side from which the laser approaches the target. This is not a TNSA process 
(reproduced by kind permission of M.Botton) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12 The dotted line shows the energy scaling of the accelerated protons as a function of the laser 
power on a snow target.  All the other points below the line show the previous experimental results given 
in (60).  
 
It should be emphasised the novel work of Zigler and his team is based on an 
acceleration mechanism that is very different from normal TNSA acceleration.  
‘Targetry’ is a rapidly advancing and critical part of ILDIAS source technology.  
 
Recent results have been published based on simulations of laser-irradiated two-layer 
targets with a linearly polarised laser pulse.  Such targets have an outer foam layer 
added to a thin solid foil. 2D PIC simulations predict 200 MeV proton yields using a 
realistic Gaussian laser pulse focussed to an intensity of 6x1020 W/cm2. (61).   
 
1.3  Angular Divergence Control (target as an ion optic) 
 
Quasi-exponential spectral profiles and large angular divergence represent significant 
technical challenges in laser-driven medical accelerator development. Mitigating beam 
line development issues attributed to the intrinsically large angular divergence and 
energy spread might require a combination of innovative ion collection optics with 
laser-plasma engineering. 
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Various methods have been used to reduce the angular divergence.  Patel et al (62) and 
Snavely et al (63) were the first to experimentally demonstrate the ballistic focusing 
capability of curved target surfaces. 
 
In 2D PIC simulations H.Y.Wang et al (64) showed that ‘bulged’ nanometer scale 
targets could generate higher energy protons  (above 124 MeV) which is a factor of 
about two greater than TNSA results from thick foil targets.  This is shown in Fig.13. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13 a) is conventional TNSA using a bulged target irradiated by a laser. Protons are grey balls and 
the electrons are the yellow cloud.  b) indicates a focussed proton beam.  Reproduced by kind permission 
of the authors and publishers. 
  
This simulation indicates that with a laser intensity of 1.3x1020 Wcm-2 the maximum 
proton energy is more than 100 MeV (with a typically broad spectrum) with a 
conversion efficiency of 24%. If the proton energy scales as the laser intensity I1/2 then 
we could expect a proton spectrum with a maximum proton energy of ~250MeV at a 
laser intensity of order 1021Wcm-2.    
 
Early experimental work by J.H.Bin et al (65) with nm diamond like carbon foils at 
8x1019 Wcm-2 laser intensity have produced 5 MeV proton beams with a divergence as 
low as 2o . This is about an order of magnitude below divergences typical of μm targets 
and can therefore enhance proton fluences by about two orders of magnitude. 
Generation and focussing of accelerated protons with a cone-shaped or cylindrically 
shaped target (downstream of the initial curved surface which provides the protons) 
T.Bartal et al (66) has also been demonstrated. In this sophisticated target assembly a 
hot electron sheath establishes a dynamic radial electric field that focuses protons 
emerging from the curved foil target. In a proof-of-concept demonstrated channeling of 
protons through the cone tip and spot size reduction have been observed in a geometry 
relevant to fast ignition for inertial fusion 
2. Beam Transport and Delivery Considerations  
 
Laser production of laser beams has yet to reach the energies and the many other 
qualities needed for deep seated tumour treatment. Nonetheless proton and carbon ion 
delivery systems have been considered for laser-driven ion beam radiotherapy (see 
1998 work entitled “Prospect for Compact Medical Laser Accelerators” (67)). For 
example, Fig. 14 illustrates a comparison between a conventional and optical gantry 
concept that has been suggested for the laser-driven case (68,69).   
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                b) 
 
 
 
 
 
 
Fig. 14  a) Conventional gantry system to direct the ion beam to the patient.  This can normally be about 
100 tons in weight and very expensive. b) The design of an optical (laser) gantry system which uses 
mirrors to convey the beam closer to the patient.  Reproduced by kind permission of the authors  (68) 
and publishers 
 
One of the most influential teams involved in developing laser-driven ion beam 
radiotherapy is in the Radiation Oncology Department at the Fox Chase Cancer Center, 
in Philadelphia. In a seminal paper in 2003 and updated in 2005 (71,72)  they presented 
calculations for the design of a spectrometer that allows for adjustable proton energy. 
A mid-plane aperture could be positioned transversely to ‘tune’ proton energy to a 
desired therapeutic energy window (see Fig. 15). The design accommodates the typical 
broad spectrum and large angular divergence of laser-accelerated protons. Furthermore, 
suitable upstream collection and collimation optics can improve the overall 
performance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15 A particle selector system originally designed by Fourkal et al (71) This particular diagram of 
similar design is presented by kind permission of Yogo et al (25).   In other variants of this system further 
focussing quadrupoles can be placed at the output.  Reproduced by kind permission of the authors and 
the publishers. 
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In a conventional accelerator driven hadron therapy unit the costs involved are so high 
that to make costs economical a number of different treatment rooms are included as 
shown in a section 7 figure. Extensive radiation shielding is required to encapsulate the 
accelerator, the f beam transfer section, the gantry systems and the multiple treatment 
rooms. The optical gantry concept (Fig. 14) suggests that the source (just the laser target 
in this case), the smaller, lighter gantry system and the patient could possibly be located 
in closer proximity. This can potentially reduce radiation shielding requirements and 
indeed the laser acceleration section requires relatively little.   
 
The shielding design for a laser–accelerated proton therapy system has been assessed 
by Fan et al (74).  Monte Carlo simulations determined the shielding necessary for 300 
MeV protons and 270 MeV electrons at a laser intensity of 2x1021Wcm-2.  Neutron 
production is a key problem and a layer of polyethylene enclosing the whole particle 
selection and collimation device was used to shield the neutrons. Encapsulating 
everything a layer of lead was used to reduce the photon dose from neutron capture and 
electron bremsstrahlung. Simulations showed that a two-layer shielding design with 10-
12 cm thick polyethylene and 4 cm thick lead can effectively absorb the unwanted 
particles to meet the necessary shielding requirements for clinical applications. 
 
A report describing all the elements for the development of a laser driven proton 
accelerator for cancer therapy was published in 2006 (75).  This paper discussed the 
treatment head of the therapy system, the specifications of the laser system, the particle 
selection and beam collimation system and an aperture based treatment optimisation 
for laser proton therapy. Other work by Ma et al (76) compares three novel approaches 
(aimed at cost effectiveness) for particle radiotherapy: dielectric wall accelerator based 
therapy systems, superconducting accelerator therapy systems and laser proton 
accelerator therapy systems. 
 
Other new developments in the field of laser driven proton therapy have been discussed 
recently by Hofmann et al (77). The work concentrates on collection and focusing of 
laser produced particles using simulated results in the high intensity Radiation Pressure 
Acceleration (RPA) regime. They present a scaling law for the “chromatic emittance” 
of the collector and apply it to the particle energy and angular spectra of the simulation 
output.  The collector in this case is a solenoid magnetic lens. For a 10 Hz laser system, 
the authors find that particle collection by a solenoid magnet satisfactorily provides the 
requirements of intensity and emittance as needed for depth scanning irradiation in a 
clinical situation. The authors conclude that without ion focussing in the laser case such 
clinical beam intensities cannot be provided. The importance of this paper is that it 
addresses the RPA mechanism which is not yet commonly studied but does provide 
insight for the near future.  
 
A more detailed subsequent paper of RPA simulations was presented by Hoffman et al 
(78).  This paper concentrates on how a beam of about 1010 protons per pulse can be 
used to irradiate tumours.  A controlled >2Gy dose on a small tumour can be achieved 
by a small number of laser pulses in seconds.  Spot scanning for conformal tumour 
irradiation requires laser pulse repetition rates exceeding 10 Hz.  The conclusions of 
this simulation show that a combination of an RPA model, solenoid, energy selection 
aperture and scatterer can result in a well characterised beam suitable for therapy 
applications.  
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Finally a number of authors (e.g. Schell and Wilkens (79)) have cautioned that much 
research still needs to be done in various areas in order to implement laser driven 
therapy in a clinical environment and that this can take many years. They base this on 
the need for increasing proton energy, reducing the broad energy spread (spectral width) 
of protons, possible limits in the pulse repetition rate and the number of accelerated 
particles per pulse.  Hofmann, Schell and Wilkins (80) do however point out that the 
short pulse nature of the laser processes may be ideal tools for motion adaption during 
radiotherapy. 
 
3. Laser Driven Electron Beams for Radiotherapy 
 
Electron beams have been used to treat cancer for more than 50 years and a review of 
electron beam therapy physics was carried out in 2006 (81).  Most electron beams 
generated clinically are in the 5-20 MeV range and, due to the more limited penetration 
depth, such beams are normally used for treatment of superficial tumours.   
 
However electron beams above 150 MeV can readily be generated with laser irradiation 
of gas targets where much less laser intensity is required compared to the case for ion 
acceleration. They have a range in tissue of about 40 cm and hence can be used to treat 
deep seated tumours. 
 
Laser-driven electron beams typically feature a quasi-monoenergetic spectral profile 
and are better directed than laser-driven ions (less lateral spread (82)).  Normally the 
laser is directed through a supersonic gas jet and the electron spectrum is measured by 
a magnetic spectrometer.  A typical electron spectrum is shown in Fig. 16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.16 Quasi-monoenergetic 225 MeV electron beam with a width of 17 MeV generated in a 4mm long 
gas jet at a density of 7x1018 cm-3  when irradiated with a 27 TW laser pulse (83). Reproduced by kind 
permission of the authors and publishers. 
  
Although most effort exploring radiotherapy of laser-driven energetic particles have 
concentrated on proton acceleration, Victor Malka and his group have considered laser-
driven electron beams for this application. They have published extensively in this area 
researching a) radiotherapy with laser-plasma accelerators (84) both experimentally 
and using Monte Carlo simulation of deposited dose and b) measuring high energy 
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electron induced damage in human carcinoma cells with electron bunches of ultrashort 
duration (85).  Treatment planning for laser accelerated very high energy electrons (now 
known as VHEE) has been carried out for prostate cancer and it has been found that the 
target coverage is better than that with a clinically approved 6 MV photon plan (86). 
 
Finally, Fig. 17 illustrates a comparison made between a measured dose distribution 
from a laser-driven 120 MeV electron beam in a phantom target and that determined in 
Monte Carlo simulation (87). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17 Measured a) and simulated b) two dimensional dose distributions in planes perpendicular to the 
beam central axis at various depths in a phantom.  As the electron beam propagates through the phantom 
multiple Coulomb scattering occurs which deflects the electrons transversely. Published by kind 
permission of the authors and publishers. 
 
The authors conclude from this work that laser-driven electron beams are quasi 
monoenergetic with low divergence and potentially are of interest for electron beam 
therapy of deep seated tumours..  The laser is more compact and delivers very high 
instantaneous doses within a time interval shorter than many chemical reactions.  
However the radiobiological effectiveness of these ultrahigh electron dose rates 
remains unknown. 
 
4.  Cellular basis of laser-driven radiation therapy 
 
Here, we address the radiobiological basis of radiation therapy. It is useful to know 
whether a certain type of radiation from a certain type of source is advantageous over 
another for tumor curability. Curability is not determined solely by the effectiveness of 
radiation to individual cells, as it is well known that there are other factors such as cell 
to cell communication and complex interactions between tissues that could affect the 
sensitivity of tissues or organs (88,89). However, knowledge from cellular radiobiology 
is at least an essential basis for assessing the effectiveness of radiation therapy. It is 
important to note that the biological effectiveness is not the only factor that determines 
the effectiveness of radiation therapy as a whole, since the energetic properties, 
reproducibility of doses among fractionated exposure, feasibility of irradiation etc, also 
affect the overall effectiveness.  
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Since this is a review of progress toward laser-driven radiotherapy it is also useful to 
know if and how the biological effect of particle radiation (radiobiological 
effectiveness, RBE) generated by lasers differs from that provided by conventional 
accelerators. This section describes basic and important issues concerning the cellular 
basis of laser-driven radiotherapy: (1) essential parameters relevant to cellular radiation 
effects, (2) the DNA damage sequence, (3) the temporal effects of high- and low-LET 
(linear energy transfer) radiation as it relates to the dose rate issue and (4) the oxygen 
effect. We also address the potential use of laser-driven radiation in radiobiological 
studies. 
 
Irradiation of certain regions within a cell, normally carried out using a sophisticated 
microbeam apparatus, could also affect the impact of irradiating the cell. However, we 
do not address microbeam effects in this work. As with therapy, one usually irradiates 
the entire cell population of a tumor as opposed to a specific cell or region of a cell. 
 
4.1 Important factors for determining cellular radiation effect 
 
Two main quantities that determine the biological effects induced by radiation are dose 
and linear energy transfer (LET). The dose to a cell is the average amount of energy 
deposited per unit mass within the cell. Extensive work has been carried out to 
determine the cellular dose-response relationship for lethality, chromosome aberration, 
mutation induction, etc.(90). Typical survival-dose response curves are shown in Fig. 
18A. LET is the average amount of energy deposited along a unit length of the track 
forged by a radiation particle such as a proton. The relative biological effectiveness 
(RBE) is the comparison of the biological effectiveness of one type of ionizing radiation 
relative to another. As such, it is the ratio of doses (of two different types of radiation) 
required to achieve a given biological effect. RBE is usually plotted against LET 
(Fig.18B) with gamma-rays or X-rays being the standard radiation type against which 
other radiation types are compared. RBE is observed to slowly vary with LET over an 
extended range. Nonetheless, it is typically at maximum levels in the high LET range, 
100-200 keV/µm which is attributed to an increased “clustering” of lesions (91,92). 
LET is the most frequently used quantity to describe the quality of a radiation type (90). 
 
 
Fig. 18. Typical dose response curves of survival of cultured mammalian cells exposed to -rays and ion 
particles with LET of ~100keV/µm (A). Typical RBE-LET relationship demonstrating that RBE peaks 
near 100-200 keV/µm (B). 
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There are significant temporal, as well as spatial, differences between high-LET and 
low-LET radiation. A substantial amount of energy is deposited in a cell by an 
individual high-LET particle track within several tens of femtoseconds. In contrast, 
individual low-LET radiation tracks deposit much less energy and it is distributed over 
the whole cell. In the low-LET case, energy is typically delivered over much longer 
timescales (usually seconds or minutes using a conventional radiation source) during 
which chemical, biochemical and biological processes occur. In general, spatially 
proximal ionization and excitation events and subsequent radical formation induced by 
a single radiation track are generally considered to be responsible for the higher RBE 
of high-LET radiation. There is growing evidence that closely localized DNA lesions 
(clustered DNA damage) are highly relevant to the ultimate biological consequences 
(91,92). It is well-known that the dose-depth profile significantly differs between 
radiation types (Fig. 1). Because of their higher LET, carbon ions have an advantage 
over protons for inactivating tumor cells. Furthermore, carbon ions are also superior in 
terms of dose localization 
 
4.2  DNA Damage Sequence and Biological Effects 
 
The time scale of sequential events for an isolated cell along a single particle (damage) 
track that lead to biological effects after irradiation (93) (Fig. 19) spans about twenty-
one orders of magnitude. Because a cell comprises mostly water (approximately 70 %), 
we focus on water radiolysis.  
 
 
 
 
 
 
 
Fig. 19. Time scales of major events that lead to biological effects of ionizing radiation. Above the scale 
bar are shown the corresponding research fields that investigate the events. 
 
The radiation effect to DNA is also considered, as it is the main target for cellular 
radiobiological effects (90) even though it constitutes only ~0.05% of the cell weight. 
After photons or particles pass through a cell, ionizations and excitations occur 
followed by dielectric relaxations. Following this initial physical stage, which occurs 
on the picosecond timescale, ions and ejected electrons will proceed to generate various 
radicals. In addition to direct ionization of DNA and DNA radicals, attacks by water-
derived radicals mainly contribute to DNA damage within the picosecond to 
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millisecond time frame. Subsequently, due to the induced DNA damage, biological 
events, such as DNA repair and cell cycle retardation can occur. If the damage is 
unrepaired and inhibits replication or cell division, cells will eventually die. 
Furthermore, a cell has a suicide pathway called apoptosis, in which a cell kills itself 
when it recognizes that the extent of damage exceeds its capacity of repair. If replication 
occurs with some damage unrepaired alterations of the DNA sequence (mutations) can 
occur. These biological events usually take place within minutes to hours. Induced 
mutations could become the origin of cancer. If the mutation is fixed in the cells from 
which egg or sperm cells are derived (germ line cells), it will lead to inherited mutation 
which is observed several decades after cells have been exposed to radiation. 
  
4.3 Dose Rate Picture  
 
The most notable difference between particle irradiation from laser-driven and 
conventional sources is the dose rate. Dose rates provided by a conventional accelerator 
are usually below 1 Gy/sec (but can be as high as ~103 Gy/sec for the spot scanning 
mode). At dose rates below 1 Gy/min, where the “low dose rate effect” is observed, the 
total irradiation time is in the range of minutes to hours. Because the irradiation time 
scale is comparable to that of DNA repair, the low dose rate effect is associated with 
repair. Previous studies have established that cellular radiosensitivity is reduced when 
cells are irradiated at such low dose rates. 
 
By contrast, with laser-driven radiation, the dose rate can exceed 109 Gy/sec and the 
irradiation time can be much shorter (typically nanoseconds). Relatively fewer studies 
have been conducted on ultra-high dose rates. One can assume that if an ultra-high dose 
rate effect exists it must be associated with specific early time physical interactions 
such as ionizations, excitations, and subsequently generated radicals. 
We attribute an ultra-high dose rate effect to events generated by neighboring tracks 
that are coincident with each other. Details of this coincidence are now explained. In 
the low-LET case (x-rays or fast electrons) the mean energy loss per collision event is 
approximately 48-64 electron volts, eV (we assume 50 eV as an average value) (93). 
The absorbed energy is converted to secondary electrons, ions and radicals. The small 
volume of ionized water and secondary electrons along the particle track is called a 
“spur”. The entire radiation track from a single particle is then a random succession of 
spurs. An ionized water molecule (H2O
+) quickly decomposes to H+aq and an OH 
radical which is mainly responsible for the DNA damage. H+aq is almost motionless 
(diffusion distance ~ 1 nm), the secondary electron range is several nm and the OH 
radical average diffusion distance is about 6 nm (and ultimately scavenged by cellular 
components)(94,95). The key issue is the proximity of a spur to DNA. DNA damage is 
correlated to a local high density of OH radicals in the volume of a nearby spur which 
can expand to as much as 5x102 nm3 according to their diffusion range. For an isolated 
cell, the coincidence responsible for an ultra-high dose rate effect (if it exists) is 
therefore the coincidence of spurs. In this picture, the temporal part of this coincidence 
(simultaneity) is limited by the spur lifetime (of order nanoseconds). The spatial part is 
limited to approximately twice the spur volume (of order 103 nm3). In the low-LET 
cases, a spur coincidence would involve multiple tracks within the short lifetime of a 
spur. For a lethal dose such as 10 Gy  (for which typical mammalian survival is less 
than 1 %) the spur density is about 10-6 nm-3 . Because the single spur volume is also 
very low, an ultra-high dose rate effect attributed to a coincidence of spurs is 
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unlikely.This conclusion is supported by laser-driven x-ray experiments (96-98), 
simulations based on precise physical/chemical parameters (99) and other experimental 
results (73). Consequently, for an isolated cell, the effect of laser-driven radiation at an 
ultra-high dose rate does not likely differ from that of radiation at a moderate or a low 
dose rate generated by conventional accelerators.  
In the high-LET case (i.e. heavier ions such as C6+), we can consider the coincidence 
of spurs along a single track where significantly more energy is deposited. The single 
track picture makes simultaneity of spurs more likely so that ultra-high dose rate effects 
in radiobiology, if they exist, are more likely to occur in response to high-LET 
irradiation. In fact, the higher RBE of high-LET radiation could be due in part to this 
temporal aspect that affords interactions between ionized or excited molecules and 
radicals within a track such that different chemical modifications may occur by multiple 
interactions in a molecule.  
In addressing dose rate, the Fig.20 describes the distribution of ionized regions (spurs) 
along a particle track and the proximity of these regions to DNA and to themselves. 
Independent of reactions and associated material responses it is useful nonetheless to 
consider simply the areal density of the particles (e.g. protons) themselves in a single 
bunch of short duration. Letting the areal track density in a cell be equal to the incident 
areal particle density of a single bunch (i.e. the longitudinal integration of volume 
density) one can estimate the areal density required for tracks to spatially overlap. 
Assuming a track area to be approximately equal to the estimated spur area of order 
100 nm2   the proton areal density required to exhibit a dose rate effect based on spatial 
overlap would exceed 1012 cm-2. For 250 MeV protons this corresponds to a volume 
density near 6x1010 cm-3 (i.e.~ 10 nC cm-3) representing a proton spacing of about 1.6 
microns (and a temporal separation of 8 femtoseconds). Although this simplistic 
argument ignores spur and track-related lifetime issues the relevant timescale is clearly 
the particle bunch duration at the cell (~ nanoseconds). 
 
Another viewpoint has also been suggested in which the time separation (and therefore 
longitudinal distance) between particles in a bunch is addressed by comparisons with 
characteristic response times of targeted cell material. In this model high dose rate 
effects (evidenced by enhanced RBE) might occur for bunch densities where the 
particle spacing is of order or less than the product of this characteristic response time 
and the particle speed (108, 109). For example a cell response time (frequency) of 10 
femtoseconds (100 THz) for 250 MeV protons is matched by a particle spacing of 2 
microns and a single bunch density near 3x1010 cm-3 (a result similar to the preceding 
simplistic estimate based on spatial overlap). This cell response picture has been 
described in terms of a proton clustering effect at high bunch densities (notably for 
ultrashort bunch durations) that could exist near the source (laser target) to boost dose 
rates by as much as two orders of magnitude.  These reported simulated results and the 
response rate hypothesis can be tested in cellular radiobiological studies. 
 
A number of other papers dealing with the dose controlled irradiation of cancer cells 
with laser accelerated proton beams, laser accelerated electron beams and x-ray beams 
including the dosimetric uncertainties introduced by the broad energy spectra of laser 
driven particle beams have been published over the years (100-103). 
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4.4  Oxygen Effect and Dose Rate 
  
We briefly consider here the cell and its environment, as opposed to the isolated cell of 
the preceding sections.  The presence of oxygen is known to enhance cell lethality by a 
factor of about 3 for low LET radiation (104). This enhancement is probably due to the 
fact that DNA radicals readily react with oxygen to generate biologically relevant DNA 
damage (105). At ultra-high dose rates (~ 109 Gy/second or more) for low LET radiation 
this oxygen effect is evident in hypoxic tissue, as several Gy dose levels deplete the 
oxygen level at such dose rates. Although oxygen is easily accessible to single 
monolayer cells, oxygen recovery to regions of diffusion-related hypoxia, which are 
often observed in a relatively small proportion of tumor tissues, can require significant 
time (several seconds for tissues having distances of more than 100µm from a tumor 
blood vessel) (104). This means that the efficiency of cell inactivation in a tumor needs 
to be optimized or improved with the mode of irradiation featuring breaks (brief time 
intervals with no irradiation) of adequate duration (~seconds) such that all cells in a 
tissue are accessible to oxygen. 
 
We suggest that this important oxygen effect also needs to be studied with laser-driven 
moderate LET (proton) irradiation, since the dose required to deplete oxygen is 
unknown and could be different with low LET irradiation. In contrast we note that high 
LET irradiation exhibits no such oxygen effect. Lethality enhancement due to the 
presence of oxygen rapidly diminishes if the LET exceeds ~ 60 KeV/micron (90). This 
is possibly attributed to the decomposition of water with high ionization density or an 
effect of the increased clustering of lesions.  
 
4.5  Laser-driven radiation in radiobiological studies 
 
In 2012 the RBE of electrons and protons was addressed (23, 106-108) and the overall 
results show no significant differences in radiobiological response for in vitro cell 
experiments between pulsed laser-accelerated and conventional clinical electron 
beams.  Much the same conclusion has been drawn in comparisons between protons 
from laser-driven and conventional accelerator sources. 
 
At this point we also address the potential use of laser-driven radiation with ultra-high 
dose rates in future radiobiological studies. A basic cellular radiobiological agenda will 
confirm the usefulness of laser-accelerated ion irradiation with effects similar to those 
generated with conventional accelerators. Although radiobiological effects which 
originate from DNA damage are less likely to exhibit any ultra-high dose effects, 
various biological endpoints derived from non-DNA targets or multi-cellular 
phenomena may indeed reveal dose rate issues. However, we expect that, under any 
circumstances, the ionized/excited molecules or radicals generated at biologically 
relevant doses should interact with one another to cause ultra-high dose rate effects. 
The use of microbeams to reduce the spatial distance between the tracks could increase 
the possibility of such interactions. One of the promising directions using laser-driven 
radiation may also involve studies of very fast physiochemical processes that take place 
within the picosecond to nanosecond timescale after irradiation of biomolecules.  
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Fig. 20. Schematic representation of the tracks of LET radiation and spurs. 
 
 
 
5. Real time Identification of healthy and cancerous tissue using Laser 
Desorption Ionization Mass Spectrometry  
 
In the 1980-90s high intensity laser driven ionization and fragmentation mass 
spectrometry was developed for the ultra-sensitive detection particularly of molecules 
(119).  The applications were principally for the sensitive detection of explosives, drugs 
of abuse and environmental pollutants. 
 
Most hydrocarbon and bio-molecules when irradiated by an intense laser beam 
fragment into moieties which are characteristic of that molecule but which usually 
contain hydrogen, carbon, oxygen, nitrogen and other atoms in certain proportions. 
 
During the last few years Takats and his team (120-124) realised that this technology 
could also be used to distinguish between healthy and diseased cancerous tissue during 
the removal of malignant tumours which can potentially enable surgery with greater 
precision and reduce the likelihood of further surgery. In particular a neurosurgery 
challenge is the distinction of where a brain tumour ends and healthy tissue begins.  
This procedure could be carried out in real time. 
 
In Fig. 21 the fragmentation patterns of certain tissues are shown and it can be seen 
from B and C the ratios of certain masses around 700 amu are different for healthy and 
diseased tissue.  The fragmentation patterns can be induced by either lasers or electrical 
high temperatures.  The ratios of the principal components (the highest mass peaks) are 
measured and it is found that the variance of any specific tissue (healthy or diseased) is 
smaller than the variance between tissue types (healthy or diseased) 
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Fig.21) This figure shows the fragmentation pattern of human tissues both healthy and diseased.  There 
are certain prominent mass peaks which are called principal components and it is found that the principal 
components of healthy and diseased tissues are sufficiently different to be used as a diagnostic technique. 
Reproduced by kind permission of Takats et al (122) and the publishers.   
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A tumour is shown in Fig.22 below surrounded by healthy tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 22 This figure shows a tumour (in blue) surrounded by healthy tissue (in green). Reproduced by 
kind permission of James  Gallacher (BBC News) (125) 
 
If we use high power lasers to produce particle beams for therapy of diseased tissues, 
we can simultaneously (& synchronously) use the laser beams to produce fragmentation 
patterns of the tissue to measure the precision of the beam therapy or surgery. The 
intrinsic capability of the laser to provide multiple synchronous beams for multiple 
related functions is one of its most valuable attributes. 
 
6 Some notable sites (current and planned) exploring laser-
acceleration and potential medical applications  
 
Initial details of the research centres and the specifications of some of the lasers 
involved in laser driven therapy and applications are given in an ICFA Publication (110) 
 
a) Queens University Belfast Consortium 
 
UK activities aimed to develop laser-driven ion sources for medical therapy are 
currently carried out within the framework of the A-SAIL consortium, which involves 
researchers at Queen’s University Belfast, University of Strathclyde, Imperial College 
and Rutherford Appleton Laboratory. This project, started in May 2013 aims to focus 
more closely on medically-related objectives. The main aim of the initiative is to 
unlock, within the next 6 years, the potential of the laser-driven ion approach as an 
alternative source for cancer therapy, advancing laser-ion sources to the point at which 
they can be a competitive alternative to conventional RF accelerators for medical 
therapy. The project aims to demonstrate controlled, all-optical acceleration of dense 
bunches of protons and other low-Z ion species in the 60-300 MeV/nucleon range of 
interest for therapy of deep-seated cancer. A number of different laser acceleration 
protocols will be studied to increase the energy of the ion beams e.g. Radiation Pressure 
Acceleration. Achieving this objective will require a coordinated effort involving 
development of new target media, understanding and controlling the physical processes 
of the relevant interaction regimes, and developing innovative solutions to known 
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difficulties. A unique property of laser-driven ion beams is their ultrashort duration 
since ions are emitted in bursts of ps or fs duration at the source and their therapeutic 
use may result in dose rates up to 9 orders of magnitude higher than normally used in 
therapy. Dose rate can be a critical parameter affecting radiation biological responses. 
The biological effects of ions at such extremes are virtually unknown, and need to be 
carefully assessed.  In parallel to the source development, the consortium is pursuing, 
by employing the unique capabilities of current and developing laser systems in terms 
of ion production and delivery, a programme of investigations of the dynamics of 
cellular response to ion irradiation and damage at these unprecedented dose rates. The 
first experiments exploring the biological effects on cells at dose rates >109 Gy/s have 
been carried out on QUB’s TARANIS laser , and recently on the GEMINI laser at RAL 
(108) 
 
b) Laboratoire d'Optique Appliquée ~ LOA, Palaiseau, France 
 
As has been described in the text, at LOA, both electron and proton beams (111) 
produced by laser plasma accelerators are considered as potential candidates for 
radiotherapy. With respect to protontherapy, LOA hosts the SAPHIR facility. The 
corresponding project called SAPHIR involves academic (groups from CNRS and 
CEA), medical groups (from Institut Gustave Roussy and Institut Curie), and industrial 
partners (Amplitude Laser Technologie, Imagine Optics and Dosisoft). The installation 
of the 200 TW laser developed by Amplitude Technologie, at LOA is now finished to 
enable first experiments. It is expected for this phase of the project that proton beams 
with energies in the few tens of MeV will be produced, and that proton beams will be 
shaped to allow the first radiobiological studies. These results will be compared to 
theoretical and simulation predictions that will help in defining the laser and target 
performances required to reach proton beams of 150-200 MeV which is necessary for 
the therapy of deep seated tumours. 
 
In addition the use of energetic electron beams for radiotherapy has been a major 
emphasis of the centre. The use of electron beams at moderate energies, 5 to 20 MeV 
range, for treating cancer and disease, is important because of the low penetration range 
in the patient. This is limited to surface tumours, i.e. tumours or disease located a few 
centimetres below the skin and with negligible dose to surrounding sensitive tissues. 
Since the range of 20 MeV electrons in water is about 10 cm while the range of 150 
MeV electrons is more than 40 cm, higher energy electrons are potentially good 
candidates for improving cancer treatment of deep seated tumours. Moreover in 
contrast to present clinical electron beams, scattering in air of high-energy electrons is 
sufficiently small that electro-magnetic pencil beam scanning is possible. This could 
benefit intensity modulated treatment where high lateral resolution is necessary. It has 
been shown that the range of energy, the charge per bunch, and the repetition rate of 
the laser satisfy many of the medical requirements for this application (84-88). Monte 
Carlo calculations have been found to be in very good agreement with dose 
measurements. Treatment planning for laser accelerated high energy electrons has 
already been carried out for prostate irradiation and further studies are scheduled for 
other organs 
 
c)  Ion Acceleration Program at BNL ATF and UCLA 
By expanding the spectral range of available laser drivers to the mid-IR region, the 9-
10m carbon dioxide (CO2) lasers offer new opportunities to explore ion acceleration. 
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Several advantages of the long-wavelength radiation, i.e. stronger ponderomotive 
electron heating and reduced critical plasma density, facilitate access to the Shock 
Wave Acceleration (SWA) regime from gas jets. Attractive features of this mechanism 
are: monoenergetic ion energy spectra, near linear ion energy scaling with the laser 
intensity, and targets of pure composition that are better suited for high repetition rate 
operation. These features have been experimentally demonstrated with picosecond CO2 
lasers operated at UCLA’s Neptune laboratory (48) where high-brightness pure proton 
beams of 3-20 MeV energy with 4-10 percent energy spread have been generated with 
supersonic hydrogen jets and at the Accelerator Test Facility (ATF) at the Brookhaven 
National Laboratory (BNL) (49). 
 
The BNL’s ATF is a DOE user facility open for international collaborations. The SWA 
experiment at ATF has been conducted in close partnership with Imperial College 
(London) and Stony Brook State University (New York). Further progress of this 
collaborative effort at ATF towards ion beams with kinetic energies suitable for  
medical applications relies on the current CO2 laser upgrade to the 50-100 TW peak 
power range. Preliminary work suggests that protons with energies approaching 100 
MeV in a quasi-monoenergetic peak may be reached if a0 values greater than 6 can be 
achieved.(112). This next-generation ultra-fast (pulse duration near 10 cycles) CO2 
laser will integrate several innovative design features such as pulse stretching and 
compression that has not been previously implemented with molecular gas lasers, 
isotopic amplifiers, and nonlinear self-chirping and filtering. 
 
When this system is completed, one of the long term campaigns will be aimed at proton 
(and other ion) acceleration by exploring collisionless shock techniques. The 
experimental work will be supported by PIC code simulations. This is to be a joint 
undertaking led by UCLA and BNL. The upgrade underway at ATF is a three-year plan 
that includes dedicated experimental space for applying laser-produced ion beams to 
user experiments with biological samples and living tissue. The Stony Brook University 
Department of Clinical Oncology will join the effort during this user stage.  
 
d) OncoRay - National Center for Radiation Research in Oncology, Dresden 
 
A long-term aim of OncoRay with its three operating partners (Technische Universität 
Dresden, University Hospital Carl Gustav Carus Dresden and Helmholtz-Zentrum 
Dresden-Rossendorf) is the development of laser-based ion-beam radiation therapy 
technology for clinical treatment of cancer patients. The necessary translational 
research from basics to clinical application and close multidisciplinary cooperation of 
physicists, engineers, biologists and physicians is supported by the German government 
(joint research project onCOOPtics pursued in cooperation with Ultraoptics Jena, 
second funding period 2012-2017), the Free State of Saxony and the European Regional 
Development Fund.   
 
During the last few years, laser-based irradiation technology has developed to such an 
extent that cell samples and small animals can be irradiated by a fixed beam line as is 
already done in ongoing systematic radiobiological experiments. Further translation 
towards clinical application is focusing on precise and efficient dose delivery to large 
tumours in patients and involves two complementary topics:  
 28 
(i) Development of energy-efficient high-power laser systems and laser targets for the 
routine generation of clinically relevant ion beams. 
(ii) Development of medical beam delivery units for laser-driven ion pulses including 
compact rotating gantries based on pulsed-power magnets, precise 3D dose monitoring 
in real-time and efficient treatment planning strategies. 
 
HZDR operates two high power laser laboratories with dedicated infrastructure for the 
investigation of laser particle sources. The first hosts a Petawatt Ti:Sapphire ultrashort-
pulse laser system (30 J in 30 fs) embedded into an accelerator laboratory. The second 
serves for the development of a fully diode-laser pumped energy-efficient solid state 
Petawatt laser that may serve as a prototype for clinical applications.    
 
A new research building was constructed on the campus of the university at a Dresden 
hospital. It is connected to the department of radio-oncology and hosts a conventional 
proton therapy facility consisting of a cyclotron, a beam line with an energy selection 
system and one treatment room with a rotating gantry (at present under commissioning, 
with the start of patient treatment in 2014). In addition, research facilities for cell and 
animal experiments as well as a Petawatt laser laboratory are available. Moreover, an 
experimental bunker allows the use of both the laser-based experimental proton beams 
and the reference beam from the cyclotron. 
 
e) Laser-acceleration Studies at JAEA in Japan 
 
Electron and proton acceleration with lasers has been an active area of investigation at 
the Kansai Photon Science Institute (KPSI) of JAEA for several years.  Researchers at 
KPSI explore candidate laser-driven proton sources and the potential for various 
applications. For example KPSI has demonstrated focusing and spectral selectivity of 
1.9 MeV protons at 1 Hz (73). The RBE of 2.3 MeV laser-accelerated protons 
irradiating invitro cells of a human salivary gland tumour has been measured with 0.2 
Gy single bunch doses delivered at 1 Hz (25,113). In recent laser experiments protons 
have been accelerated to energies as high as ~ 43 MeV (cut-off value) with an on-target 
laser intensity (power) of 1021 W/cm2 (200 TW) and an intensity contrast at the 10-10 
level (136).  
 
Experiments have been supported historically by strong laser-plasma simulation efforts 
(see for example 44, 45-51). Furthermore, in collaboration with the University of 
Bologna, the University of Milano and INFN  the use of multi-layered targets as sources 
combined with candidate charge collection/transport optics have been investigated in 
simulations of a hybrid ILDIAS (i.e. HILDIAS) in which final acceleration to a desired 
operating proton energy is accomplished using a conventional compact side-coupled 
RF linac) (137).  
 
Currently, the J-KAREN laser at KPSI is being upgraded to higher pulse power and 
repetition-rate capability (with the upgraded result to be renamed as J-KAREN-P). J-
KAREN-P will deliver an on-target peak power of ~ PW at 0.1 Hz with improved 
focusing and intensity contrast. This will enable extended secondary source studies. 
With higher intensity on target KPSI aims to make notable progress toward reaching ~ 
200 MeV proton energies as well as KeV x-rays. 
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f) The Munich Centre for Advanced Photonics (MAP)  
 
The Munich-Centre for Advanced Photonics (MAP, http://www.munichphotonics.de) 
is a research cluster funded by the German government since 2000. MAP draws on 
recent developments in high-power laser technology and emerging secondary sources 
of laser-driven X-rays and laser-driven particle beams for (i) imaging and early 
detection of small tumours (before they can form metastases) and (ii) high-precision 
image-guided local radiation therapy. As previously discussed, laser-based particle 
acceleration (in particular of protons and carbon ions) offers the potential of compact 
and cost-efficient sources that could replace conventional cyclotrons or synchrotrons. 
This means that more cancer patients (both with small and advanced tumours) could 
benefit from particle beam radiotherapy and particularly in countries where RF 
conventional accelerator based technology is too expensive. 
 
Researchers at MAP are currently investigating the required physical, technological and 
biological basis for laser-based radiation therapy with proton or carbon ion beams. They 
focus on these issues both from a fundamental physics point of view as well as with 
respect to applied medical physics and radiobiology with the long term goal of 
developing a laser-based particle therapy unit. In particular, the ion acceleration process 
itself is studied using ultra-thin diamond-like carbon foils as targets, and a laser-driven 
biomedical beamline for cellular radiation biology and dosimetry has been constructed.  
 
As soon as higher proton energies (250 MeV) will be available, radiobiological 
investigations will shift to pre-clinical studies in mice and finally towards clinically 
relevant setups. Appropriate methods for beam delivery including lateral and axial 
beam shaping for highly pulsed beams and the corresponding treatment planning 
strategies are being developed in order to design clinical treatment units for laser-driven 
particle beams. These activities are pursued by MAP and at the new facility “Centre for 
Advanced Laser Applications” (CALA), a dedicated new building on the Garching 
research campus (near Munich). The long-term goal is development of an integrated, 
laser-based system for high-resolution phase-contrast X-ray imaging and particle 
therapy of tumours. 
 
g) ELIMED Prague 
 
The ELIMED (ELI MEDical applications) research project has been launched by 
INFN-LNS and ASCR-FZU researchers within the pan-European ELI-Beamlines 
facility framework. The ELIMED project aims to demonstrate potential 
multidisciplinary user applications of laser-accelerated proton beams. In this picture 
eye melanoma (uveal melanoma which is normally treated with 62 MeV proton beams 
produced by standard accelerators) will be considered as a model case to demonstrate 
a potential future use of laser-driven protons in hadrontherapy; especially because of 
the limited constraints on proton energy and irradiation geometry for this particular 
tumour treatment. 
Several challenges, starting from laser-target interaction and beam transport 
development up to dosimetry and radiobiology, need to be overcome in order to reach 
the ELIMED final goals. A crucial role will be played by the final design and realization 
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of a transport beamline capable of providing ion beams with proper characteristics in 
terms of the energy spectrum and angular distribution which will allow performing 
dosimetric tests and biological cell irradiation. A preliminary prototype transport 
beamline has been designed and some transport elements are under construction for 
first experimental tests at the TARANIS laser system. 
A wide international collaboration among specialists of different disciplines like 
physics, biology, chemistry, medicine and physicians coming from Europe, Japan, and 
the US is growing around the ELIMED project. The aim is to create a network of 
specialists proposing conceptual designs, and technical and scientific solutions likely 
to be implemented at the ELI Beamlines facility. 
h) Selcuk/Strathclyde Consortium Konya, Turkey 
Initially the existing lasers in Konya will be applied to studying laser ablation 
fragmentation patterns of both healthy and cancerous tissue from both animal and 
human tissue (120-124).  This research will afford determination of tumour edges with 
greater precision. Along with precision surgical procedures this will reduce the 
incidence of re-growth of tumours that  can necessitate future surgery. Selcuk 
University and the University of Strathclyde are part of an international collaboration 
(TILADIA) to carry out tissue analysis by direct laser desorption mass spectrometry for 
the stratified diagnostics of cancer patients.  This is headed by Dr. Takats (Imperial 
College). 
Following research with tissue analysis, laser-acceleration of protons to ~ 70 MeV 
energy will be pursued to enable irradiation of small animal tumours. This program is 
expected to take about two years to complete. The potential for direct irradiation of 
tumours inside the body by high power lasers via optical fibres will also be investigated 
(i.e. use the tumour as a target to produce the proton beams). This has the added 
attraction of requiring less energetic protons to irradiate deep seated tumours. The 
longer term vision is to site an international centre at the Selcuk University Hospital to 
develop laser driven proton and heavy ion beams for cancer therapy. 
7. Comparative Radiotherapy Costs  
 
We stated in the preamble that there are some 39 conventional accelerator centres 
around the world used for proton and heavy ion cancer therapy.  The sites in Europe 
are shown in Fig. 23 
 
It has been mentioned (3) that particle therapy is potentially a more effective therapeutic 
procedure than photon therapy.  How costly is particle therapy?  Andrea Peeters et al 
(114) have estimated the capital costs for a) combined proton /carbon facility, b) proton 
only facility and c) photon facility to be a) 139 million €, b) 95 million € and c) 23 
million €.   
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Fig. 23  Proton and ion therapy centres in Europe  Reproduced by kind permission of the Dr Andrzej 
Kacperek ,Clatterbridge Centre,Liverpool 
 
The relative cost of treatment can also depend on where the tumour is located. The high 
cost of accelerator hadron treatment is evident when one considers the size of a typical 
hadron therapy facility (as shown for example in Fig 24). The cost figures presented in 
Peeters et al are very similar to those cited in (3). 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24 The Rinecker Proton Therapy Center in Munich.  The large capital costs can be mitigated if a 
number of treatment areas are provided which results in more patients being treated.  It is important to 
point out that in the future costs could be further reduced if compact cyclotrons are used. 
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Two very important systematic literature reviews of the clinical cost-effectiveness of 
conventional accelerator driven hadron therapy were carried out in 2007 and 2012 
(12,115). The conclusion of the first survey was “existing data do not suggest that the 
rapid expansion of hadron therapy (HT) as a major modality would be appropriate.  
Further research into clinical and cost-effectiveness of HT is needed.”  In the second 
survey some 5 years later, this conclusion was slightly tempered with the “aim of 
building enough proton therapy facilities and run clinical trials to draw firm conclusions 
about the clinical effectiveness of charged particle therapy to best current practice”. 
 
The cost of establishing a laser-based therapy centre can potentially be much cheaper 
although one must be cautious here because all essential components must be 
considered and no centre has yet been built. Significant cost reduction in the laser case 
can be possible if a) future  high power lasers become much more compact and can 
therefore be housed in a smaller building b) radiation shielding can be significantly 
reduced and c) if an optical gantry were possible that could be lighter and smaller than 
that associated with a conventional accelerator-based system. Costs for a laser-driven 
facility have been estimated by a number of authors to be between 10-20 million € 
(75,114,115). The Thales laser company recently developed the Bella laser (at a cost 
near $11 million) which is used at the Lawrence Berkeley National Laboratory. With 
petawatt peak power capability it has potential for accelerating protons to energies 
suitable for radiotherapy (116). 
Although most developing countries would find the costs required for a conventional 
accelerator-based hadron therapy centre to be prohibitive they might find a laser-based 
system to be more affordable given national budgets. These countries could potentially 
afford 5-10 million € to initiate a laser-driven beam centre that can guide future 
innovation. Such startup laser systems may not be able to provide 250 MeV protons for 
deep tumour therapy but they can establish the necessary foundation and suitably 
comprehensive thinking. 
 
Finally it should be emphasised that the center costs mentioned in this section are 
limited to the cyclotron and treatment rooms and for the basic laser and a single 
treatment room.  Like-for-like comparisons have not been made rigorously for the two 
approaches to proton therapy. 
 
8. Discussion and Conclusions 
 
Before discussing in detail where we are with laser driven ion beams for oncology we 
comment briefly on possible controversies concerning the effectiveness of ion beam 
radiotherapy in general (i.e. with conventional accelerator driven proton and heavy ion 
beams).  Two very important papers addressing this ongoing debate have recently been 
published (126,128).  There is no question that charged particle radiation therapy offers 
significant advantages in physical dose distributions (Bragg Peak – Fig.1), however the 
authors of these two papers are questioning whether better physical dose distribution 
necessarily results in overall clinical benefit. The conclusions of these papers strongly 
suggest that randomised trials would remain the preferred goal to test the effectiveness 
of proton and heavy ion therapy.  In addition, establishing a European Hadron Therapy 
Register (or better an International Register) to make better use of the data being 
generated by the many existing hadron therapy centres would be greatly beneficial.  A 
further controversial article was published in the Biology and Medicine Journal ( 
entitled “Is spending on proton beam therapy for cancer going too far too fast” (128).  
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However in answer to this paper a group of UK oncologists claimed the report 
misrepresented the approach being used in the UK (129).  Epstein claims that despite 
huge amounts of money being put into building accelerators for proton therapy the first 
randomised trial is just beginning and won’t be completed for seven years. 
 
In this work the essence of these considerations for the future is the development of 
reliable, controlled laser-driven sources (photons and particles) for medical application. 
Since we must wait seven years for completion of the first randomised trial that is 
testing the efficacy of conventional accelerator driven proton therapy, it is relevant to 
speculate about the anticipated state of laser-driven hadron therapy in the future.  A 
number of articles dealing with the prospects for and progress towards laser proton 
therapy have been published especially in the last year dealing with this question 
(117,129-133,) with estimated time frames of 4-10 years or longer being suggested for 
implementing laser driven ion beam radiotherapy (shorter time estimates apply to 
ocular tumours for which required proton energies are ~ 70 MeV). 
 
With appropriate targetry, contrast and focusing PW level lasers will likely accelerate 
proton and ion beams to kinetic energies that are relevant to radiotherapy of deep seated 
tumours. Over the next few years these systems will likely continue to be very large 
and very expensive. Thus to deliver the vision of a compact, affordable ILDIAS much 
“thinking out of the box” could be necessary to deliver better targets, better lasers and 
better beam delivery. In the broader context of fully functional integrated laser-driven 
systems (ILDIAS and ILDEAS) it is clear that considerable progress must still be made 
if we hope to realize laser-driven accelerators with medically relevant beam parameters 
and performance levels suitable for clinical usage. Meanwhile, the path toward laser-
driven energetic particle beams of medical quality will no doubt also enable other 
important ‘en route’ applications that can serve to highlight ongoing progress and 
multiple laser-driven capabilities. 
 
Although many researchers at high power laser laboratories around the world make 
reference enthusiastically to laser-driven proton radiotherapy, time on these lasers to 
develop the necessary clinical requirements can be quite limited and such applications 
are  typically treated as a lower priority. There is little doubt that realizing concrete 
progress toward the laser-driven radiotherapy vision requires a laser centre that is 
dedicated to laser-driven accelerator development for radiotherapy and a variety of 
other applications.  A dedicated centre for laser-driven particle beam lines and other 
secondary sources such as x-ray beams will highlight key unique features of laser-
driven secondary sources. A centre like this would also need a laser-driven radiobiology 
program, biomedical technology program to support such applications and a globally 
coordinated preclinical science agenda. Throughout, the centre should remain adaptive 
to new developments. An overall programmatic strategy that is built around key 
intermediate milestone applications (not necessarily medical) is strongly 
recommended.  
 
In conclusion we recognise that the state-the-art for ion beam radiotherapy (IBRT) is 
not static. Therefore comparisons with the laser-case (and with other cases) can be 
dynamic. For example, in parallel with progress made in the laser-case, commercial 
development of compact cyclotrons (notably superconducting synchrocyclotrons) and 
associated gantries is ongoing. A good example is the recent developments led by IBA 
to commercially provide a KHz proton source with nanoampere current at a kinetic 
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energy up to 250 MeV (134,135). As with the optical gantry for the laser case, 
embedding an adequately compact cyclotron source into a single gantry is being 
considered. So, evolution of the cost/size comparison is not attributed solely to laser 
system development.  It is clear that new source development for medical applications 
must be monitored continually and comprehensively. 
 
With lasers in mind, it is therefore critical to identify noteworthy features of laser-
driven particle acceleration that can also be unique. The potential for spectral (particle 
energy) control in the delivery of therapeutic treatment, for sophisticated targetry (for 
example, that can also function as an ion optic) and for particle bunches of high charge, 
short duration and very low emittance are some examples. The flexibility that a laser-
driven source can afford is also noteworthy. This includes the potential for multiple 
particle beams that can include different  ion species as well as an intrinsic synchronized 
multiple beam capability that can feature secondary (laser-driven) x-ray sources and 
diagnostic laser probes to accompany energetic particle beams. Of course, the requisite 
laser-plasma engineering needed to realize such capabilities is a great technical 
challenge that can be addressed at a centre that is dedicated to ILDIAS development. 
As the relevant laser, laser-plasma and target science and technologies mature we 
remain optimistic that cost/size comparisons will become increasingly favourable and 
the therapy niche increasingly clear. 
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